FDA has approved paclitaxel protein-bound particles for injectable suspension) (albumin-bound) (Abraxane, Celgene) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

FDA approves therapy for first-line treatment of advanced NSCLC

Newsletter